Document Detail

Pharmacoeconomics of levocetirizine in allergic rhinitis and chronic idiopathic urticaria: considerations for the USA.
MedLine Citation:
PMID:  20528375     Owner:  NLM     Status:  PubMed-not-MEDLINE    
BACKGROUND: Levocetirizine, a recent, second-generation oral antihistamine, was approved by the US FDA in May 2007 to treat symptoms of allergic rhinitis and chronic idiopathic urticaria.
OBJECTIVE: To review the economic literature for levocetirizine.
METHODS: Two reviewers conducted a systematic review of the literature to identify abstracts that met the inclusion criteria. Abstracts that were considered acceptable were retrieved with full text for further assessment.
RESULTS: A total of 82 potential studies were identified. After reviewing abstracts, 11 articles were preselected for potential inclusion. Of the 11 full-text articles, three articles met the inclusion criteria.
CONCLUSION: The pharmacoeconomic literature for levocetirizine was limited. The findings were consistent across the literature, suggesting levocetirizine improved outcomes, leading to incremental cost savings and cost-effectiveness. Since many of the available levocetirizine data come from European studies, differences in practice patterns and medical resources should be considered when extrapolating data to a US clinical setting.
Lawrence M Dubuske; Brian Seal; Martin Cj Brown
Related Documents :
19411505 - Methodological issues in systematic reviews and meta-analyses of observational studies ...
19186345 - Treatment regimens of acupuncture for low back pain--a systematic review.
11770685 - Fungi: toxic killers or unavoidable nuisances?
19905035 - Assessing comparative effectiveness research in the us.
22796195 - Case report of a congenital lingual leiomyomatous hamartoma: new epidemiologic findings...
6968525 - Emergency care of the hemophiliac patient.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Expert review of pharmacoeconomics & outcomes research     Volume:  8     ISSN:  1744-8379     ISO Abbreviation:  Expert Rev Pharmacoecon Outcomes Res     Publication Date:  2008 Jun 
Date Detail:
Created Date:  2010-06-10     Completed Date:  2012-10-02     Revised Date:  2014-07-30    
Medline Journal Info:
Nlm Unique ID:  101132257     Medline TA:  Expert Rev Pharmacoecon Outcomes Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  233-41     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Gefitinib: a consideration of cost.
Next Document:  NCIC Clinical Trials Group experience of employing patient-reported outcomes in clinical trials: an ...